MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded re-accreditation to the Personalis Clinical Laboratory, Menlo Park, California based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
The Personalis Clinical Laboratory, Personalis Inc., was advised of this national recognition and congratulated for the excellence of the services being provided. The Personalis Clinical Laboratory is one of more than 8,000 CAP-accredited facilities worldwide.
“In addition to receiving CAP re-accreditation, we are very pleased there were no deficiencies noted during this re-inspection, in line with a Personalis Clinical Laboratory trend since first receiving CAP Accreditation in 2014,” said Massimo Morra, MD PhD FACMG, Senior Clinical Laboratory Director at Personalis. Dr. Morra also added, “This accomplishment is a testament to the outstanding service provided by the entire Personalis Team and their commitment to the Clinical Laboratory operation.”
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, READ THE CAP ANNUAL REPORT at cap.org.
About Personalis, Inc.
Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.